Meta-analysiscited by the Tayebat archiveabstract only checked A-SUP-12 standard review
Cochrane: omega-3 and heart health
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Overview
Abdelhamid AS et al.. Cochrane Database Syst Rev 2020 · PMID 32114706 · DOI 10.1002/14651858.CD003177.pub5
Little or no effect on deaths; small reductions in coronary events (low certainty).
Does the study support the specific claim? Partly · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Omega-3 effects.
- How was the study done?
Cochrane review.
- How many people, animals or samples were studied?
162,796.
- What was actually found?
Little effect on death; small CHD benefit.
- How large was the observed effect?
RR 0.91 CHD events.
- What do the results mean in everyday life?
Modest benefit at most.
- What are the study's limitations?
Low certainty.
- What does it say about Elawady's specific claim?
Mixed.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Large benefits.
Scientific in-depth review
1. Full reference
- Authors
- Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, Summerbell CD, Worthington HV, Song F, Hooper L
- Journal
- Cochrane Database Syst Rev
- Year
- 2020
- Identifier
- PMID 32114706 DOI 10.1002/14651858.CD003177.pub5 · PMC7049091
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
ASA: none known
TJB: none known
JSB: none known
PB: none known
GCT: none known
HJM: none known
KHOD: none known
FKA: none known
CDS: none known
HVW: none known
FS: none known
LH: none known
2. Research question
Effects of omega-3 fats on mortality, CV events, adiposity, lipids
3. Study design and population
- Study design
- Meta-analysis – Cochrane systematic review and meta-analysis of RCTs
- Population
Adults in 86 RCTs
- Country
Mainly high-income countries
- Period
to Feb 2019
- Sample size
86 RCTs, 162,796
- Inclusion and exclusion criteria
see abstract
4. Methods and endpoints
- Exposure / intervention
Increased LCn3 or ALA
- Comparator
Usual/lower intake
- Endpoints
Mortality, CV events, etc.
- Statistical methods
Random effects; GRADE
5. Actual results
- Results
LCn3: all-cause mortality RR 0.97 (0.93–1.01, high certainty); CV events RR 0.96 (0.92–1.01); CHD mortality RR 0.90 (0.81–1.00, low); CHD events RR 0.91 (0.85–0.97, low); arrhythmia RR 0.99; triglycerides −15%.
- Absolute risks
not reported in abstract
- Authors' conclusion
LCn3 slightly reduces CHD mortality and events and reduces triglycerides; ALA slightly reduces CV events and arrhythmia.
6. Strengths
- Comprehensive Cochrane review
- GRADE
7. Weaknesses
- Low certainty for small benefits
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
AMSTAR-2-oriented: high quality.
9. Assessment of the statistical interpretation
See results.
10. Relevance to the specific claim
11. Independent contrary findings
12. Transferability to Germany and Europe
High: biology and trial populations comparable to European adults.
13. Overall methodological judgement
Best overall synthesis; mixed relative to archive claim.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | high |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | mixed |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | taken out of context |
14. Open questions
15. Linked fact checks
- When popular oral supplements (calcium, beta-carotene, vitamin E, omega-3, multivitamins, glucosamine, selenium, vitamin A) were tested in large long-term placebo-controlled trials, most failed to deliver the promised prevention of disease. – Studies with mixed or unclear results
- Omega-3 capsules do not prevent cardiovascular disease and increase the risk of atrial fibrillation; Elawady rejects omega-3 capsules. – Studies with mixed or unclear results
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Listed in the archive bibliography of the oral-supplements rule without its own interpretation; used implicitly to support the rule summary that supplements 'failed or caused harm' in large trials.
- A. What was actually studied?
Effects of omega-3 fats on mortality, CV events, adiposity, lipids
- B. What did the authors find?
LCn3: all-cause mortality RR 0.97 (0.93–1.01, high certainty); CV events RR 0.96 (0.92–1.01); CHD mortality RR 0.90 (0.81–1.00, low); CHD events RR 0.91 (0.85–0.97, low); arrhythmia RR 0.99; triglycerides −15%.
- C. What conclusions do the authors themselves draw?
LCn3 slightly reduces CHD mortality and events and reduces triglycerides; ALA slightly reduces CV events and arrhythmia.
- D. What does the archive derive from it?
Cited as if supporting 'omega-3 failed'.
- E. Is this derivation scientifically justified?
Only partly: the review finds little or no effect on mortality but small benefits on CHD that the archive does not mention.
- Adequacy of the interpretation (by the archive)
- taken out of context